{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:53:24Z","timestamp":1790974404146,"version":"4.1.0"},"reference-count":202,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Urinary biomarkers are promising tools in urological oncology because urine can be collected non-invasively and repeatedly during diagnosis, treatment, and surveillance. Despite extensive biomarker discovery, their adoption in routine practice remains limited. Biomarker performance depends not only on analytical accuracy but also on the clinical decision, anatomical route into urine, biological source of the signal, specimen fraction, and timing and conditions of sampling. This review evaluates urinary biomarkers across bladder cancer, upper-tract urothelial carcinoma, prostate cancer, and renal cell carcinoma using a biologically grounded, decision-oriented framework. It considers tumor-derived nucleic acids, epigenetic alterations, proteins, immune and inflammatory mediators, extracellular vesicles, metabolites, microbiome-associated signals, and multiparametric models. Bladder cancer represents the most anatomically direct and clinically mature setting, with potential applications in hematuria evaluation, cystoscopy triage, recurrence surveillance, molecular residual disease assessment, and monitoring of response to bacillus Calmette\u2013Gu\u00e9rin therapy. In upper-tract urothelial carcinoma, distinguishing voided from selectively collected urine is essential because dilution, transit, obstruction, and limited localization affect interpretation. Prostate urine assays are best positioned for biopsy triage and refinement of active surveillance rather than general population screening. Renal cell carcinoma biomarkers remain exploratory because the sources and mechanisms of urinary signal release are insufficiently resolved. Clinical translation should be assessed using decision-specific outcomes, including incremental value, calibration, net clinical benefit, procedures avoided, significant cancers missed, reproducibility, and feasibility, rather than diagnostic accuracy or area under the receiver operating characteristic curve alone.<\/jats:p>","DOI":"10.3390\/diagnostics16172810","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:31:13Z","timestamp":1788251473000},"page":"2810","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Urinary Biomarkers in Urological Oncology: From Biological Origin to Clinical Decision-Making\u2014A Narrative Review"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7981-8603","authenticated-orcid":false,"given":"Aliya","family":"Nurmukhanbetova","sequence":"first","affiliation":[{"name":"General Immunology Department, Asfendiyarov Kazakh National Medical University, Almaty 050054, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassymkhan","family":"Sultanbekov","sequence":"additional","affiliation":[{"name":"Department of Public Health and Healthcare, South Kazakhstan Medical Academy, Shymkent 160019, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khussan","family":"Umurzakov","sequence":"additional","affiliation":[{"name":"Urooncology Center, Kazakh Institute of Oncology and Radiology, Almaty 050022, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zie","family":"Gassanov","sequence":"additional","affiliation":[{"name":"Urooncology Center, Kazakh Institute of Oncology and Radiology, Almaty 050022, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Altyn","family":"Duisenbayeva","sequence":"additional","affiliation":[{"name":"Department of General Medical Practice No. 2, Asfendiyarov Kazakh National Medical University, Almaty 050054, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alimkhan","family":"Talas","sequence":"additional","affiliation":[{"name":"Department of General Medical Practice No. 2, Asfendiyarov Kazakh National Medical University, Almaty 050054, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazzat","family":"Shaikenova","sequence":"additional","affiliation":[{"name":"Department of Clinical Disciplines, University of International Business Named After Kenzhegali Sagadiev, Almaty 050010, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5390-4623","authenticated-orcid":false,"given":"Aidos","family":"Bolatov","sequence":"additional","affiliation":[{"name":"Shenzhen University Medical School, Shenzhen University, Shenzhen 518037, China"},{"name":"Department of Science, \u201cUniversity Medical Center\u201d Corporate Fund, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/14737159.2020.1743687","article-title":"Update on urine as a biomarker in cancer: A necessary review of an old story","volume":"20","author":"Zhang","year":"2020","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Sequeira-Antunes, B., and Ferreira, H.A. (2023). Urinary Biomarkers and Point-of-Care Urinalysis Devices for Early Diagnosis and Management of Disease: A Review. Biomedicines, 11.","DOI":"10.3390\/biomedicines11041051"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s13258-025-01680-5","article-title":"Emerging technologies and clinical translation of urine-based liquid biopsy in urological cancers","volume":"47","author":"Yoon","year":"2025","journal-title":"Genes Genom."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s40242-026-5303-1","article-title":"Urine-based Biomarkers: Progress, Challenges, and Prospects","volume":"42","author":"Wu","year":"2026","journal-title":"Chem. Res. Chin. Univ."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e70124","DOI":"10.1002\/bco2.70124","article-title":"Urinary biomarkers in multicentric studies: Shaping the future of bladder cancer diagnosis and follow-up","volume":"6","author":"Martel","year":"2025","journal-title":"BJUI Compass"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Yang, Z., Song, F., and Zhong, J. (2025). Urinary Biomarkers in Bladder Cancer: FDA-Approved Tests and Emerging Tools for Diagnosis and Surveillance. Cancers, 17.","DOI":"10.20944\/preprints202510.0625.v1"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41585-023-00818-y","article-title":"Diagnostic liquid biopsy biomarkers in renal cell cancer","volume":"21","author":"Zieren","year":"2024","journal-title":"Nat. Rev. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kelly, J.F., Samarska, I.V., Ramaekers, B., Marcelissen, T., van Roermund, J.G., Aarts, M.J.B., Kerkhofs, T., Hermans, T., van Osch, F., and de Meyer, T. (2025). Renal cell carcinoma detection: A systematic review in diagnostic urinary biomarkers. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14900-8"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11934-017-0748-x","article-title":"Recent Developments in the Search for Urinary Biomarkers in Bladder Cancer","volume":"18","author":"Leiblich","year":"2017","journal-title":"Curr. Urol. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Aveta, A., Cilio, S., Contieri, R., Spena, G., Napolitano, L., Manfredi, C., Franco, A., Crocerossa, F., Cerrato, C., and Ferro, M. (2023). Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202305.1974.v1"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Hentschel, A.E., van den Helder, R., van Trommel, N.E., van Splunter, A.P., van Boerdonk, R.A.A., van Gent, M.D.J.M., Nieuwenhuijzen, J.A., and Steenbergen, R.D.M. (2021). The Origin of Tumor DNA in Urine of Urogenital Cancer Patients: Local Shedding and Transrenal Excretion. Cancers, 13.","DOI":"10.3390\/cancers13030535"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2023.07.014","article-title":"Field Cancerization Is Associated with Tumor Development, T-cell Exhaustion, and Clinical Outcomes in Bladder Cancer","volume":"85","author":"Strandgaard","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2025.12.054","article-title":"Field-effect-informed urine liquid biopsy for bladder cancer","volume":"189","author":"Shi","year":"2026","journal-title":"Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/14737159.2019.1675515","article-title":"Clinical utility of emerging biomarkers in prostate cancer liquid biopsies","volume":"20","author":"Boerrigter","year":"2020","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_15","first-page":"PO.20.00060","article-title":"Emerging Roles of Urine-Based Tumor DNA Analysis in Bladder Cancer Management","volume":"4","author":"Chaudhuri","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e2300362","DOI":"10.1200\/PO.23.00362","article-title":"Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates","volume":"8","author":"Satyal","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"433.e19","DOI":"10.1016\/j.urolonc.2023.07.007","article-title":"Feasibility and tissue concordance of genomic sequencing of urinary cytology in upper tract urothelial carcinoma","volume":"41","author":"Katims","year":"2023","journal-title":"Urol. Oncol."},{"key":"ref_18","first-page":"770","article-title":"Urinary biomarkers of prostate cancer","volume":"25","author":"Fujita","year":"2018","journal-title":"Int. J. Urol. Off. J. Jpn. Urol. Assoc."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Borbiev, T., Kohaar, I., and Petrovics, G. (2023). Clinical Biofluid Assays for Prostate Cancer. Cancers, 16.","DOI":"10.3390\/cancers16010165"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13073-020-00723-8","article-title":"Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors","volume":"12","author":"Smith","year":"2020","journal-title":"Genome Med."},{"key":"ref_21","first-page":"208","article-title":"Urinary markers for bladder cancer diagnosis: A review of current status and future challenges","volume":"31","author":"Tomiyama","year":"2024","journal-title":"Int. J. Urol. Off. J. Jpn. Urol. Assoc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e20240045","DOI":"10.1084\/jem.20240045","article-title":"Urine scRNAseq reveals new insights into the bladder tumor immune microenvironment","volume":"221","author":"Tran","year":"2024","journal-title":"J. Exp. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1152\/physrev.00041.2019","article-title":"The Urothelium: Life in a Liquid Environment","volume":"100","author":"Dalghi","year":"2020","journal-title":"Physiol. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1590\/s1677-5538.ibju.2020.0021","article-title":"Preoperative hydronephrosis predicts adverse pathological features and postoperative survival in patients with high-grade upper tract urothelial carcinoma","volume":"47","author":"Qian","year":"2021","journal-title":"Int. Braz. J. Urol. Off. J. Braz. Soc. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/1878-0261.13628","article-title":"Unlocking the potential of tumor-derived DNA in urine for cancer detection: Methodological challenges and opportunities","volume":"19","author":"Wever","year":"2025","journal-title":"Mol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.21037\/tau-20-1039","article-title":"Urinary extracellular vesicles: A rising star in bladder cancer management","volume":"10","author":"Urabe","year":"2021","journal-title":"Transl. Androl. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6230409","DOI":"10.1155\/2019\/6230409","article-title":"Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Gu\u00e9rin for Bladder Cancer","volume":"2019","author":"Liu","year":"2019","journal-title":"J. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1038\/s41598-024-55251-x","article-title":"Cross-sectional and longitudinal analyses of urinary extracellular vesicle mRNA markers in urothelial bladder cancer patients","volume":"14","author":"Murakami","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"533","DOI":"10.32604\/or.2024.055155","article-title":"Biomarkers for predicting bladder cancer therapy response","volume":"33","author":"Mihai","year":"2025","journal-title":"Oncol. Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Uzelac, M., Xin, R., Chen, T., John, D., Li, W.T., Rajasekaran, M., and Ongkeko, W.M. (2024). Urinary Microbiome Dysbiosis and Immune Dysregulations as Potential Diagnostic Indicators of Bladder Cancer. Cancers, 16.","DOI":"10.3390\/cancers16020394"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1002\/ijc.34434","article-title":"Urine biomarkers in cancer detection: A systematic review of preanalytical parameters and applied methods","volume":"152","author":"Jordaens","year":"2023","journal-title":"Int. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12967-022-03414-7","article-title":"An optimized method for the isolation of urinary extracellular vesicles for molecular phenotyping: Detection of biomarkers for radiation exposure","volume":"20","author":"Hinzman","year":"2022","journal-title":"J. Transl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Wang, X., Zhang, S., Wu, L., Feng, B., Shen, H., Gu, Y., Zhang, Q., Fang, F., Yang, R., and Guo, H. (2022). Diagnostic performance of an immunoassay based on urine exfoliated cell enrichment nanotechnology for upper tract urothelial carcinoma: A retrospective, monocentric study. BMC Urol., 22.","DOI":"10.1186\/s12894-022-01122-4"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Oyaert, M., Van Praet, C., Delrue, C., and Speeckaert, M.M. (2025). Novel Urinary Biomarkers for the Detection of Bladder Cancer. Cancers, 17.","DOI":"10.3390\/cancers17081283"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Chauhan, P.S., Chen, K., Babbra, R.K., Feng, W., Pejovic, N., Nallicheri, A., Harris, P.K., Dienstbach, K., Atkocius, A., and Maguire, L. (2021). Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study. PLoS Med., 18.","DOI":"10.1371\/journal.pmed.1003876"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.euo.2024.09.016","article-title":"Minimal Residual Disease Detection with Urine-derived DNA Is Prognostic for Recurrence-free Survival in Bacillus Calmette-Gu\u00e9rin-unresponsive Non-muscle-invasive Bladder Cancer Treated with Nadofaragene Firadenovec","volume":"8","author":"Narayan","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Lim, C.J., Nguyen, P.H.D., Wasser, M., Kumar, P., Lee, Y.H., Nasir, N.J.M., Chua, C., Lai, L., Hazirah, S.N., and Loh, J.J.H. (2021). Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.615091"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Duggan, B., O\u2019Rourke, D., Anderson, N., Reid, C.N., Watt, J., O\u2019Kane, H., Boyd, R., Curry, D., Evans, M., and Stevenson, M. (2022). Biomarkers to assess the risk of bladder cancer in patients presenting with haematuria are gender-specific. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1009014"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41391-020-0237-z","article-title":"Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10\u2009ng\/mL","volume":"23","author":"Tutrone","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.04.012","article-title":"Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score","volume":"70","author":"Hendriks","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-14-3334","article-title":"Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer","volume":"21","author":"Leyten","year":"2015","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0302-2838(03)00201-X","article-title":"DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer","volume":"44","author":"Hessels","year":"2003","journal-title":"Eur. Urol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eururo.2015.04.039","article-title":"Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment","volume":"70","author":"Tomlins","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Satyal, U., Srivastava, A., and Abbosh, P.H. (2019). Urine Biopsy-Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01266"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1126\/science.aba8347","article-title":"Extensive heterogeneity in somatic mutation and selection in the human bladder","volume":"370","author":"Lawson","year":"2020","journal-title":"Science"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1126\/science.aba7300","article-title":"Macroscopic somatic clonal expansion in morphologically normal human urothelium","volume":"370","author":"Li","year":"2020","journal-title":"Science"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"104551","DOI":"10.1016\/j.isci.2022.104551","article-title":"The origin of bladder cancer from mucosal field effects","volume":"25","author":"Bondaruk","year":"2022","journal-title":"iScience"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Joseph, M., and Enting, D. (2019). Immune Responses in Bladder Cancer-Role of Immune Cell Populations, Prognostic Factors and Therapeutic Implications. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01270"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Annels, N.E., Simpson, G.R., and Pandha, H. (2020). Modifying the Non-muscle Invasive Bladder Cancer Immune Microenvironment for Optimal Therapeutic Response. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00175"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Pan, S., Li, S., Zhan, Y., Chen, X., Sun, M., Liu, X., Wu, B., Li, Z., and Liu, B. (2022). Immune status for monitoring and treatment of bladder cancer. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.963877"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e012050","DOI":"10.1136\/jitc-2025-012050","article-title":"T cell subsets of urine-derived lymphocytes (UDLs) serve as an indicator of TILs and reflect immunological sex differences in bladder cancer","volume":"13","author":"Schafer","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1084\/jem.20181003","article-title":"Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment","volume":"215","author":"Wong","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Furuya, H., Chan, O.T.M., Hokutan, K., Tsukikawa, Y., Chee, K., Kozai, L., Chan, K.S., Dai, Y., Wong, R.S., and Rosser, C.J. (2019). Prognostic Significance of Lymphocyte Infiltration and a Stromal Immunostaining of a Bladder Cancer Associated Diagnostic Panel in Urothelial Carcinoma. Diagnostics, 10.","DOI":"10.3390\/diagnostics10010014"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Crocetto, F., Falcone, A., Mirto, B.F., Sicignano, E., Pagano, G., Dinacci, F., Varriale, D., Machiella, F., Giampaglia, G., and Calogero, A. (2024). Unlocking Precision Medicine: Liquid Biopsy Advancements in Renal Cancer Detection and Monitoring. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25073867"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Netti, G.S., De Luca, F., Camporeale, V., Khalid, J., Leccese, G., Troise, D., Sanguedolce, F., Stallone, G., and Ranieri, E. (2025). Liquid Biopsy as a New Tool for Diagnosis and Monitoring in Renal Cell Carcinoma. Cancers, 17.","DOI":"10.3390\/cancers17091442"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Wu, P., Zhang, G., Zhao, J., Chen, J., Chen, Y., Huang, W., Zhong, J., and Zeng, J. (2018). Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China. Front. Cell. Infect. Microbiol., 8.","DOI":"10.3389\/fcimb.2018.00429"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Russo, F., Tripodi, L., Caldora, F., Pandolfo, S.D., Aveta, A., Nardelli, C., Imbimbo, C., Perdon\u00e0, S., Pastore, L., and Castaldo, G. (2026). Identification of a weighted urinary microbial signature for bladder cancer discrimination. Front. Oncol., 16.","DOI":"10.3389\/fonc.2026.1784501"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Kim, S.J., Park, M., Choi, A., and Yoo, S. (2024). Microbiome and Prostate Cancer: Emerging Diagnostic and Therapeutic Opportunities. Pharmaceuticals, 17.","DOI":"10.3390\/ph17010112"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"447","DOI":"10.5173\/ceju.2024.80","article-title":"Genitourinary microbiomes and prostate cancer: A systematic review and meta-analysis of tumorigeneses and cancer characteristics","volume":"77","author":"Parizi","year":"2024","journal-title":"Cent. Eur. J. Urol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00345-024-05173-0","article-title":"A review of urinary bladder microbiome in patients with bladder cancer and its implications in bladder pathogenesis","volume":"42","author":"Stamatakos","year":"2024","journal-title":"World J. Urol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Randazzo, G., Bovolenta, E., Ceccato, T., Reitano, G., Betto, G., Novara, G., Iafrate, M., Morlacco, A., Dal Moro, F., and Zattoni, F. (2024). Urinary microbiome and urological cancers: A mini review. Front. Urol., 4.","DOI":"10.3389\/fruro.2024.1367720"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ctrv.2018.05.012","article-title":"Novel urinary biomarkers for the detection of bladder cancer: A systematic review","volume":"69","author":"Tan","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.21037\/tcr-21-386","article-title":"Diagnostic and prognostic role of BTA, NMP22, survivin and cytology in urothelial carcinoma","volume":"10","author":"Gong","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13148-016-0303-5","article-title":"UroMark-a urinary biomarker assay for the detection of bladder cancer","volume":"9","author":"Feber","year":"2017","journal-title":"Clin. Epigenet."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13148-022-01335-2","article-title":"BladMetrix: A novel urine DNA methylation test with high accuracy for detection of bladder cancer in hematuria patients","volume":"14","author":"Pharo","year":"2022","journal-title":"Clin. Epigenet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.euo.2021.10.003","article-title":"Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis","volume":"4","author":"Laukhtina","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1158\/2159-8290.CD-18-0825","article-title":"Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA","volume":"9","author":"Dudley","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Katsimperis, S., Tzelves, L., Feretzakis, G., Bellos, T., Tsikopoulos, I., Kostakopoulos, N., and Skolarikos, A. (2025). Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: Implications for Prognosis and Treatment Personalization. Cancers, 17.","DOI":"10.3390\/cancers17121908"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6278","DOI":"10.1172\/JCI139597","article-title":"Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Newman, A., Hansel, S., Gerrard, G., Orton, L., Chandra, A., Nair, R., Del Giudice, F., Ibrahim, Y., Mensah, E., and Khan, M.S. (2026). Real-World Evaluation of Uromonitor\u00ae for Bladder Cancer Detection and Surveillance. Cancers, 18.","DOI":"10.3390\/cancers18101650"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Fiorentino, V., Pizzimenti, C., Franchina, M., Rossi, E.D., Tralongo, P., Carlino, A., Larocca, L.M., Martini, M., Fadda, G., and Pierconti, F. (2023). Bladder Epicheck Test: A Novel Tool to Support Urothelial Carcinoma Diagnosis in Urine Samples. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241512489"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Castellano, E., Samba, C., Esteso, G., Simpson, L., Vendrame, E., Garc\u00eda-Cuesta, E.M., L\u00f3pez-Cobo, S., \u00c1lvarez-Maestro, M., Linares, A., and Leibar, A. (2022). CyTOF analysis identifies unusual immune cells in urine of BCG-treated bladder cancer patients. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.970931"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","article-title":"Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Kamat","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Ashiru, O., Esteso, G., Garc\u00eda-Cuesta, E.M., Castellano, E., Samba, C., Escudero-L\u00f3pez, E., L\u00f3pez-Cobo, S., \u00c1lvarez-Maestro, M., Linares, A., and Ho, M.M. (2019). BCG Therapy of Bladder Cancer Stimulates a Prolonged Release of the Chemoattractant CXCL10 (IP10) in Patient Urine. Cancers, 11.","DOI":"10.3390\/cancers11070940"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrurol.2016.252","article-title":"Diagnostic dilemmas in patients with upper tract urothelial carcinoma","volume":"14","author":"Baard","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1007\/s00345-023-04530-9","article-title":"Consultation on UTUC II Stockholm 2022: Diagnostics, prognostication, and follow-up-where are we today?","volume":"41","author":"Baard","year":"2023","journal-title":"World J. Urol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00345-016-1820-8","article-title":"Investigating upper urinary tract urothelial carcinomas: A single-centre 10-year experience","volume":"35","author":"Dev","year":"2017","journal-title":"World J. Urol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Bitaraf, M., Ghafoori Yazdi, M., and Amini, E. (2023). Upper Tract Urothelial Carcinoma (UTUC) Diagnosis and Risk Stratification: A Comprehensive Review. Cancers, 15.","DOI":"10.3390\/cancers15204987"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/JU.0000000000004803","article-title":"Diagnostic Accuracy of the Oncuria-Detect Multiplex Immunoassay in Detecting Upper Tract Urothelial Carcinoma","volume":"215","author":"Fujita","year":"2026","journal-title":"J. Urol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Giudici, N., Blarer, J., Sathianathen, N., Burkhard, F.C., Wuethrich, P.Y., Thalmann, G.N., Seiler, R., and Furrer, M.A. (2024). Diagnostic Value of Urine Cytology in Pharmacologically Forced Diuresis for Upper Tract Urothelial Carcinoma Diagnosis and Follow-Up. Cancers, 16.","DOI":"10.20944\/preprints202401.0673.v1"},{"key":"ref_81","first-page":"221","article-title":"Diagnostic role of urine cytology and ureteroscopic biopsies in detection of high grade upper tract urothelial carcinoma","volume":"9","author":"Zhao","year":"2021","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.21037\/tau-24-326","article-title":"Diagnostic status and new explorations in upper urinary tract urothelial carcinoma: A literature review","volume":"13","author":"Shan","year":"2024","journal-title":"Transl. Androl. Urol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.21037\/tau.2019.11.28","article-title":"Ureteroscopic biopsy of upper tract urothelial carcinoma and role of urinary biomarkers","volume":"9","author":"Smentkowski","year":"2020","journal-title":"Transl. Androl. Urol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Bia\u0142ek, \u0141., Bilski, K., Dobruch, J., Krajewski, W., Szyde\u0142ko, T., Kryst, P., and Poletajew, S. (2022). Non-Invasive Biomarkers in the Diagnosis of Upper Urinary Tract Urothelial Carcinoma-A Systematic Review. Cancers, 14.","DOI":"10.3390\/cancers14061520"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jasc.2018.07.006","article-title":"Utility of The Paris System for Reporting Urinary Cytology in upper urinary tract specimens","volume":"7","author":"Xing","year":"2018","journal-title":"J. Am. Soc. Cytopathol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jasc.2023.12.003","article-title":"Utility of The Paris System (TPS) for upper urinary tract cytopathology: Correlation with histology follow-up and UroVysion fluorescence in situ hybridization (FISH) analysis","volume":"13","author":"Jia","year":"2024","journal-title":"J. Am. Soc. Cytopathol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"26106","DOI":"10.18632\/oncotarget.15344","article-title":"Fluorescence in situ hybridization status of voided urine predicts invasive and high-grade upper tract urothelial carcinoma","volume":"8","author":"Su","year":"2017","journal-title":"Oncotarget"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12032-018-1237-x","article-title":"Fluorescence in situ hybridization in 1 mL of selective urine for the detection of upper tract urothelial carcinoma: A feasibility study","volume":"36","author":"Freund","year":"2018","journal-title":"Med. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1111\/cas.14000","article-title":"Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma","volume":"110","author":"Hayashi","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.humpath.2021.09.007","article-title":"Upper urothelial tract high-grade carcinoma: Comparison of urine cytology and DNA methylation analysis in urinary samples","volume":"118","author":"Pierconti","year":"2021","journal-title":"Hum. Pathol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/ajcp\/aqad116","article-title":"Comparison of DNA methylation and cytology tests in urine to detect upper tract urothelial carcinoma: A paired-design diagnostic study","volume":"161","author":"Wei","year":"2024","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/JU.0000000000003480","article-title":"Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA\/SUO Guideline","volume":"209","author":"Coleman","year":"2023","journal-title":"J. Urol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00345-016-1859-6","article-title":"Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: Treatment of low-risk upper tract urothelial carcinoma","volume":"35","author":"Mandalapu","year":"2017","journal-title":"World J. Urol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.21037\/tau.2020.03.47","article-title":"Bladder tumor recurrence after urothelial carcinoma of the upper urinary tract","volume":"9","author":"Lonergan","year":"2020","journal-title":"Transl. Androl. Urol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.euros.2023.01.004","article-title":"Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management Strategies","volume":"49","author":"Mertens","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.eururo.2018.08.019","article-title":"A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng\/ml at Initial Biopsy","volume":"74","author":"McKiernan","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/JU.0000000000004421","article-title":"Clinical Validation of MyProstateScore 2.0 Testing Using First-Catch, Non-Digital Rectal Examination Urine","volume":"213","author":"Tosoian","year":"2025","journal-title":"J. Urol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Bajo-Santos, C., Brok\u0101ne, A., Zayakin, P., Endzeli\u0146\u0161, E., Sobo\u013cevska, K., Belovs, A., Jansons, J., Sperga, M., Llorente, A., and Radovi\u010da-Spalvi\u0146a, I. (2023). Plasma and urinary extracellular vesicles as a source of RNA biomarkers for prostate cancer in liquid biopsies. Front. Mol. Biosci., 10.","DOI":"10.3389\/fmolb.2023.980433"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41391-022-00562-1","article-title":"Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer","volume":"25","author":"Visser","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Bellei, E., Caramaschi, S., Giannico, G.A., Monari, E., Martorana, E., Reggiani Bonetti, L., and Bergamini, S. (2023). Research of Prostate Cancer Urinary Diagnostic Biomarkers by Proteomics: The Noteworthy Influence of Inflammation. Diagnostics, 13.","DOI":"10.3390\/diagnostics13071318"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1001\/jamaoncol.2024.0455","article-title":"Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer","volume":"10","author":"Tosoian","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Huskova, Z., Knillova, J., Kolar, Z., Vrbkova, J., Kral, M., and Bouchal, J. (2020). The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy. Biomedicines, 8.","DOI":"10.3390\/biomedicines8060173"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1159\/000506885","article-title":"Impact of Histopathological Prostate Inflammation on Urine-Based Prostate Cancer Prediction Using the Prostate Cancer Gene 3 Score","volume":"104","author":"Hennenlotter","year":"2020","journal-title":"Urol. Int."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrurol.2017.167","article-title":"The inflammatory microenvironment and microbiome in prostate cancer development","volume":"15","author":"Sfanos","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.eururo.2019.06.023","article-title":"Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis","volume":"77","author":"Drost","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa2100852","article-title":"STHLM3 consortium MRI-Targeted or Standard Biopsy in Prostate Cancer Screening","volume":"385","author":"Eklund","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.eururo.2008.06.071","article-title":"Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy","volume":"54","author":"Haese","year":"2008","journal-title":"Eur. Urol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Matuszczak, M., Schalken, J.A., and Salagierski, M. (2021). Prostate Cancer Liquid Biopsy Biomarkers\u2019 Clinical Utility in Diagnosis and Prognosis. Cancers, 13.","DOI":"10.3390\/cancers13133373"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5534\/wjmh.230386","article-title":"Liquid Biomarkers in Prostate Cancer Diagnosis: Current Status and Emerging Prospects","volume":"43","author":"Liu","year":"2025","journal-title":"World J. Men\u2019s Health"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/JU.0000000000001361","article-title":"Clinical Utility of 4Kscore\u00ae, ExosomeDx\u2122 and Magnetic Resonance Imaging for the Early Detection of High Grade Prostate Cancer","volume":"205","author":"Fasulo","year":"2021","journal-title":"J. Urol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.euo.2020.12.004","article-title":"Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis","volume":"4","author":"Mazzone","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.urology.2021.11.033","article-title":"Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need","volume":"164","author":"Tosoian","year":"2022","journal-title":"Urology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11255-023-03786-9","article-title":"Utility of noninvasive biomarker testing and MRI to predict a prostate cancer diagnosis","volume":"56","author":"Sultan","year":"2024","journal-title":"Int. Urol. Nephrol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/s41391-021-00367-8","article-title":"Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: A prospective, multicenter study in biopsy-na\u00efve men","volume":"24","author":"Hendriks","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"132","DOI":"10.21037\/tau.2017.12.29","article-title":"Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease","volume":"7","author":"Schoots","year":"2018","journal-title":"Transl. Androl. Urol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2214\/AJR.20.23985","article-title":"Update on Multiparametric Prostate MRI During Active Surveillance: Current and Future Trends and Role of the PRECISE Recommendations","volume":"216","author":"Giganti","year":"2021","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Erdmann, K., Distler, F., Gr\u00e4fe, S., Kwe, J., Erb, H.H.H., Fuessel, S., Pahernik, S., Thomas, C., and Borkowetz, A. (2024). Transcript Markers from Urinary Extracellular Vesicles for Predicting Risk Reclassification of Prostate Cancer Patients on Active Surveillance. Cancers, 16.","DOI":"10.3390\/cancers16132453"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.euros.2023.10.005","article-title":"Magnetic Resonance Imaging-guided Active Surveillance Without Annual Rebiopsy in Patients with Grade Group 1 or 2 Prostate Cancer: The Prospective PROMM-AS Study","volume":"59","author":"Valentin","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Lakshminarayanan, H., Rutishauser, D., Schraml, P., Moch, H., and Bolck, H.A. (2020). Liquid Biopsies in Renal Cell Carcinoma-Recent Advances and Promising New Technologies for the Early Detection of Metastatic Disease. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.582843"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1016\/S0022-5347(05)64991-9","article-title":"Renal cell carcinoma invading the urinary collecting system: Implications for staging","volume":"167","author":"Uzzo","year":"2002","journal-title":"J. Urol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"21325","DOI":"10.1038\/srep21325","article-title":"Prognostic role of urinary collecting system invasion in renal cell carcinoma: A systematic review and meta-analysis","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/bju.13669","article-title":"Urinary collecting system invasion is associated with poor survival in patients with clear-cell renal cell carcinoma","volume":"119","author":"Bailey","year":"2017","journal-title":"BJU Int."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"251403","DOI":"10.1155\/2015\/251403","article-title":"Serum and urine biomarkers for human renal cell carcinoma","volume":"2015","author":"Pastore","year":"2015","journal-title":"Dis. Markers"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"620","DOI":"10.21037\/tcr.2017.05.19","article-title":"Renal cell carcinoma: The search for a reliable biomarker","volume":"6","author":"Farber","year":"2017","journal-title":"Transl. Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4065\/mcp.2009.0709","article-title":"Urinary biomarkers for the early diagnosis of kidney cancer","volume":"85","author":"Morrissey","year":"2010","journal-title":"Mayo Clin. Proc."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/jamaoncol.2015.0213","article-title":"Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations as Biomarkers to Screen for Renal Cell Carcinoma: A Prospective Cohort Study","volume":"1","author":"Morrissey","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Cricr\u00ec, G., Bellucci, L., Montini, G., and Collino, F. (2021). Urinary Extracellular Vesicles: Uncovering the Basis of the Pathological Processes in Kidney-Related Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126507"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"C1439","DOI":"10.1152\/ajpcell.00349.2023","article-title":"Exploring the role of urinary extracellular vesicles in kidney physiology, aging, and disease progression","volume":"325","author":"Grange","year":"2023","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41581-024-00914-1","article-title":"Protein handling in kidney tubules","volume":"21","author":"Hall","year":"2025","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41581-024-00819-z","article-title":"Physiological principles underlying the kidney targeting of renal nanomedicines","volume":"20","author":"Huang","year":"2024","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_131","first-page":"260","article-title":"Urinary aquaporin 1 and perilipin 2: Can these novel markers accurately characterize small renal masses and help guide patient management?","volume":"26","author":"Song","year":"2019","journal-title":"Int. J. Urol. Off. J. Jpn. Urol. Assoc."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Zhu, H., Wang, X., Lu, S., and Ou, K. (2023). Metabolic reprogramming of clear cell renal cell carcinoma. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1195500"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Lameirinhas, A., Miranda-Gon\u00e7alves, V., Henrique, R., and Jer\u00f3nimo, C. (2019). The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma. Genes, 10.","DOI":"10.3390\/genes10040264"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Liu, X., Zhang, M., Liu, X., Sun, H., Guo, Z., Tang, X., Wang, Z., Li, J., Li, H., and Sun, W. (2019). Urine Metabolomics for Renal Cell Carcinoma (RCC) Prediction: Tryptophan Metabolism as an Important Pathway in RCC. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00663"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Falegan, O.S., Arnold Egloff, S.A., Zijlstra, A., Hyndman, M.E., and Vogel, H.J. (2019). Urinary Metabolomics Validates Metabolic Differentiation Between Renal Cell Carcinoma Stages and Reveals a Unique Metabolic Profile for Oncocytomas. Metabolites, 9.","DOI":"10.3390\/metabo9080155"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Bifarin, O.O., Gaul, D.A., Sah, S., Arnold, R.S., Ogan, K., Master, V.A., Roberts, D.L., Bergquist, S.H., Petros, J.A., and Edison, A.S. (2021). Urine-Based Metabolomics and Machine Learning Reveals Metabolites Associated with Renal Cell Carcinoma Stage. Cancers, 13.","DOI":"10.3390\/cancers13246253"},{"key":"ref_137","first-page":"101318","article-title":"Molecular signature of renal cell carcinoma by means of a multiplatform metabolomics analysis","volume":"31","author":"Kordalewska","year":"2022","journal-title":"Biochem. Biophys. Rep."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41591-020-0933-1","article-title":"Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes","volume":"26","author":"Nuzzo","year":"2020","journal-title":"Nat. Med."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Peter, M.R., Zhao, F., Jeyapala, R., Kamdar, S., Xu, W., Hawkins, C., Evans, A.J., Fleshner, N.E., Finelli, A., and Bapat, B. (2022). Investigating Urinary Circular RNA Biomarkers for Improved Detection of Renal Cell Carcinoma. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.814228"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"117672","DOI":"10.1016\/j.cca.2023.117672","article-title":"Urinary-derived extracellular vesicle microRNAs as non-invasive diagnostic biomarkers for early-stage renal cell carcinoma","volume":"552","author":"Zhang","year":"2024","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1681\/ASN.2018080853","article-title":"Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities","volume":"30","author":"Estrada","year":"2019","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1136\/jcp-2023-209173","article-title":"Clinicopathological features of kidney injury in patients receiving immune checkpoint inhibitors (ICPi) combined with anti-vascular endothelial growth factor (anti-VEGF) therapy","volume":"77","author":"Jin","year":"2024","journal-title":"J. Clin. Pathol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1002\/1878-0261.13639","article-title":"Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer","volume":"18","author":"Vedeld","year":"2024","journal-title":"Mol. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update","volume":"84","author":"Seisen","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.eururo.2022.09.008","article-title":"Elevated T-cell Exhaustion and Urinary Tumor DNA Levels Are Associated with Bacillus Calmette-Gu\u00e9rin Failure in Patients with Non-muscle-invasive Bladder Cancer","volume":"82","author":"Strandgaard","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/ijc.33327","article-title":"The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder","volume":"148","author":"Mason","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Delrue, C., De Bruyne, S., Speeckaert, R., and Speeckaert, M.M. (2023). Urinary Extracellular Vesicles in Chronic Kidney Disease: From Bench to Bedside?. Diagnostics, 13.","DOI":"10.3390\/diagnostics13030443"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Oh, S., and Kwon, S.H. (2021). Extracellular Vesicles in Acute Kidney Injury and Clinical Applications. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168913"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1038\/s41598-017-05623-3","article-title":"Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer","volume":"7","author":"Patel","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/JU.0000000000005130","article-title":"Urine Tumor DNA Testing Identifies Recurrence and Monitors Therapy Response in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer Receiving Intravesical Bacillus Calmette-Gu\u00e9rin","volume":"216","author":"Bahlburg","year":"2026","journal-title":"J. Urol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/1055-9965.EPI-18-0893","article-title":"Urinary Cytokine Profile to Predict Response to Intravesical BCG with or without HS-410 Therapy in Patients with Non-muscle-invasive Bladder Cancer","volume":"28","author":"Salmasi","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Bourlotos, G., Baigent, W., Hong, M., Plagakis, S., and Grundy, L. (2024). BCG induced lower urinary tract symptoms during treatment for NMIBC-Mechanisms and management strategies. Front. Neurosci., 17.","DOI":"10.3389\/fnins.2023.1327053"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/ng.3692","article-title":"Clonal evolution of chemotherapy-resistant urothelial carcinoma","volume":"48","author":"Faltas","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.molonc.2016.08.003","article-title":"Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma","volume":"10","author":"Thomsen","year":"2016","journal-title":"Mol. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41585-020-0304-1","article-title":"Genomic heterogeneity in bladder cancer: Challenges and possible solutions to improve outcomes","volume":"17","author":"Meeks","year":"2020","journal-title":"Nat. Rev. Urol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41586-024-07955-3","article-title":"The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution","volume":"635","author":"Nguyen","year":"2024","journal-title":"Nature"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/cas.16025","article-title":"Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma","volume":"115","author":"Tamura","year":"2024","journal-title":"Cancer Sci."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e70120","DOI":"10.1002\/jev2.70120","article-title":"Roadblocks of Urinary EV Biomarkers: Moving Toward the Clinic","volume":"14","author":"Droste","year":"2025","journal-title":"J. Extracell. Vesicles"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41568-025-00882-z","article-title":"Unlocking the potential of urine-based liquid biopsy through improved reporting and standardization","volume":"26","author":"Ward","year":"2026","journal-title":"Nat. Rev. Cancer"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13148-022-01240-8","article-title":"Bladder cancer detection in urine using DNA methylation markers: A technical and prospective preclinical validation","volume":"14","author":"Hentschel","year":"2022","journal-title":"Clin. Epigenet."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Harvey, J.C., Cambridge, L.M., Ellen, C.W., Colonval, M., Hazlett, J.A., Newell, J., Zhou, X., and Guilford, P.J. (2024). Analytical Validation of Cxbladder\u00ae Detect, Triage, and Monitor: Assays for Detection and Management of Urothelial Carcinoma. Diagnostics, 14.","DOI":"10.3390\/diagnostics14182061"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41467-020-20493-6","article-title":"Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer","volume":"12","author":"Vandekerkhove","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e1008","DOI":"10.1002\/ctm2.1008","article-title":"Non-invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study","volume":"12","author":"Xiao","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41698-022-00345-w","article-title":"Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients","volume":"7","author":"Chauhan","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41512-019-0064-7","article-title":"A simple, step-by-step guide to interpreting decision curve analysis","volume":"3","author":"Vickers","year":"2019","journal-title":"Diagn. Progn. Res."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1158\/1055-9965.EPI-23-1594","article-title":"Designing Rigorous and Efficient Clinical Utility Studies for Early Detection Biomarkers","volume":"33","author":"Zheng","year":"2024","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Dom\u00ednguez, R., Gonz\u00e1lez-Dom\u00ednguez, \u00c1., Sayago, A., and Fern\u00e1ndez-Recamales, \u00c1. (2020). Recommendations and Best Practices for Standardizing the Pre-Analytical Processing of Blood and Urine Samples in Metabolomics. Metabolites, 10.","DOI":"10.3390\/metabo10060229"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Lee, J., Kim, E., Park, J., Choi, S., Lee, M.S., and Park, J. (2023). Pre-analytical handling conditions and protein marker recovery from urine extracellular vesicles for bladder cancer diagnosis. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0291198"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Ko\u015bli\u0144ski, P., Pluskota, R., M\u0105dra-Gackowska, K., Gackowski, M., Markuszewski, M.J., K\u0119dziora-Kornatowska, K., and Koba, M. (2020). Comparison of Pteridine Normalization Methods in Urine for Detection of Bladder Cancer. Diagnostics, 10.","DOI":"10.3390\/diagnostics10090612"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Gontero, P., Mariappan, P., Pradere, B., Rai, B.P., Liedberg, F., Comp\u00e9rat, E., Teoh, J.Y., Moschini, M., Soria, F., and van Rhijn, B.W.G. (Eur. Urol., 2026). EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS)\u2014A Summary of the 2026 Guidelines Update, Eur. Urol., in press.","DOI":"10.1016\/j.eururo.2026.04.009"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline: 2024 Amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J. Urol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.eururo.2025.02.023","article-title":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: Summary of the 2025 Update","volume":"87","author":"Birtle","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_174","unstructured":"Masson-Lecomte, A., Baard, J., Birtle, A., Comp\u00e9rat, E.M., Dominguez-Escrig, J.L., Gontero, P., Liedberg, F., Mariappan, P., Pradere, B., and Rai, B.P. (2026, August 15). EAU Guidelines on Upper Urinary Tract Urothelial Carcinoma. European Association of Urology. Available online: https:\/\/uroweb.org\/guidelines\/upper-urinary-tract-urothelial-cell-carcinoma."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Wei 2026, J.T., Barocas, D., Carlsson, S., Coakley, F., Eggener, S., Etzioni, R., Fine, S.W., Han, M., Kim, S.K., and Kirkby, E. (2023). Early Detection of Prostate Cancer: AUA\/SUO Guideline Part II: Considerations for a Prostate Biopsy. J. Urol., 210, 54\u201363.","DOI":"10.1097\/JU.0000000000003492"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Cornford, P., van den Bergh, R.C.N., Briers, E., Chiu, P., Eberli, D., Epure, A., Farolfi, A., Fonteyne, V., Gandaglia, G., and Gillessen, S. (Eur. Urol., 2026). EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening Diagnosis, and Local Treatment with Curative Intent, Eur. Urol., in press.","DOI":"10.1016\/j.eururo.2026.04.013"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/JU.0000000000004995","article-title":"Updates to Early Detection of Prostate Cancer: AUA\/SUO Guideline (2026)","volume":"215","author":"Lin","year":"2026","journal-title":"J. Urol."},{"key":"ref_178","unstructured":"Bex, A., Abu-Ghanem, Y., Bedke, J., Breen, D.J., Capitanio, U., Dabestani, S., Hora, M., Klatte, T., Kuusk, T., and Lund, L. (2026, August 15). EAU Guidelines on Renal Cell Carcinoma. European Association of Urology. Available online: https:\/\/uroweb.org\/guidelines\/renal-cell-carcinoma."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"e12093","DOI":"10.1002\/jev2.12093","article-title":"Urinary extracellular vesicles: A position paper by the Urine Task Force of the International Society for Extracellular Vesicles","volume":"10","author":"Blijdorp","year":"2021","journal-title":"J. Extracell. Vesicles"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1038\/s41388-025-03624-5","article-title":"From concept to clinic: A roadmap for DNA methylation biomarkers in liquid biopsies","volume":"44","author":"Pharo","year":"2025","journal-title":"Oncogene"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Sutton, A.J., Lamont, J.V., Evans, R.M., Williamson, K., O\u2019Rourke, D., Duggan, B., Sagoo, G.S., Reid, C.N., and Ruddock, M.W. (2018). An early analysis of the cost-effectiveness of a diagnostic classifier for risk stratification of haematuria patients (DCRSHP) compared to flexible cystoscopy in the diagnosis of bladder cancer. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0202796"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s40273-023-01256-9","article-title":"Critical Appraisal of Decision Models Used for the Economic Evaluation of Bladder Cancer Screening and Diagnosis: A Systematic Review","volume":"41","author":"Mandrik","year":"2023","journal-title":"PharmacoEconomics"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00345-023-04389-w","article-title":"Cost-effectiveness of an urinary biomarker panel in combination with MRI for prostate cancer diagnosis","volume":"41","author":"Govers","year":"2023","journal-title":"World J. Urol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eururo.2025.03.018","article-title":"Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial","volume":"88","author":"Dreyer","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.euo.2025.04.020","article-title":"Results of the Prospective Randomized UroFollow Trial Comparing Marker-guided Versus Cystoscopy-based Surveillance in Patients with Low\/Intermediate-risk Bladder Cancer","volume":"8","author":"Bismarck","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Choochuen, P., Sangkhathat, S., Chiangjong, W., Attawettayanon, W., Leetanaporn, K., Surachat, K., Sukpan, P., Kaewrattana, W., Senkhum, O., and Khongcharoen, N. (2025). Integrated Proteogenomic Approach for Discovering Potential Biomarkers in Urothelial Carcinoma of the Bladder. Biomedicines, 13.","DOI":"10.3390\/biomedicines13123020"},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Hentschel, A.E., Nieuwenhuijzen, J.A., Bosschieter, J., Splunter, A.P.V., Lissenberg-Witte, B.I., Voorn, J.P.V., Segerink, L.I., Moorselaar, R.J.A.V., and Steenbergen, R.D.M. (2020). Comparative Analysis of Urine Fractions for Optimal Bladder Cancer Detection Using DNA Methylation Markers. Cancers, 12.","DOI":"10.3390\/cancers12040859"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/s41467-025-57633-9","article-title":"Urinary extracellular vesicle N-glycomics identifies diagnostic glycosignatures for bladder cancer","volume":"16","author":"Li","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Katzendorn, O., von Klot, C.A.J., Mahjoub, S., Faraj Tabrizi, P., Harke, N.N., Tezval, H., Hellms, S., Hennenlotter, J., Baig, M.S., and Stenzl, A. (2022). Combination of PI-RADS score and mRNA urine test-A novel scoring system for improved detection of prostate cancer. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0271981"},{"key":"ref_190","first-page":"e1396","article-title":"Can the predictive value of multiparametric MRI for prostate cancer be improved by a liquid biopsy with SelectMDx?","volume":"4","author":"Bach","year":"2021","journal-title":"Cancer Rep."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41391-022-00538-1","article-title":"Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: A systematic review and diagnostic meta-analysis","volume":"25","author":"Yanagisawa","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Maggi, M., Del Giudice, F., Falagario, U.G., Cocci, A., Russo, G.I., Di Mauro, M., Sepe, G.S., Galasso, F., Leonardi, R., and Iacona, G. (2021). SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study. Cancers, 13.","DOI":"10.3390\/cancers13092047"},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Biti\u0146a-Barlote, \u0112., B\u013ciz\u0146uks, D., Sili\u0146a, S., \u0160atcs, M., Vjaters, E., Lietuvietis, V., Nakazawa-Mikla\u0161evi\u010da, M., Plonis, J., Mikla\u0161evi\u010ds, E., and Daneberga, Z. (2025). Liquid Biopsy Based Bladder Cancer Diagnostic by Machine Learning. Diagnostics, 15.","DOI":"10.3390\/diagnostics15040492"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41585-025-01122-7","article-title":"A multi-modal approach for decision making in bladder cancer","volume":"23","author":"Ding","year":"2026","journal-title":"Nat. Rev. Urol."},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Altynova, S., Saliev, T., Asanova, A., Kozybayeva, Z., Rakhimzhanova, S., and Bolatov, A. (2026). Artificial Intelligence and Predictive Modelling for Precision Dosing of Immunosuppressants in Kidney Transplantation. Pharmaceuticals, 19.","DOI":"10.3390\/ph19010165"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: Updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"e081554","DOI":"10.1136\/bmj-2024-081554","article-title":"FUTURE-AI Consortium FUTURE-AI: International consensus guideline for trustworthy and deployable artificial intelligence in healthcare","volume":"388","author":"Lekadir","year":"2025","journal-title":"BMJ"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"e082505","DOI":"10.1136\/bmj-2024-082505","article-title":"PROBAST+AI: An updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods","volume":"388","author":"Moons","year":"2025","journal-title":"BMJ"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.eururo.2018.08.038","article-title":"Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators","volume":"74","author":"Wynants","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"e078276","DOI":"10.1136\/bmj-2023-078276","article-title":"Developing clinical prediction models: A step-by-step guide","volume":"386","author":"Efthimiou","year":"2024","journal-title":"BMJ"},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Bayanova, M., Saliev, T., Zhakupov, A., Abdikadirova, A., Sapargaliyeva, M., Ibraimov, B., and Bolatov, A. (2026). Biomarkers of Treatment Response in Paediatric Medulloblastoma. Diagnostics, 16.","DOI":"10.3390\/diagnostics16071089"},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Bolatov, A., Zhakupov, A., Sapargaliyeva, M., Abdikadirova, A., Xu, X., and Bayanova, M. (2026). Cerebrospinal Fluid in Pediatric Neuro-Oncology: Molecular Diagnosis, Disease Monitoring, and Clinical Translation. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27115010"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/17\/2810\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:41:14Z","timestamp":1788252074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/17\/2810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":202,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["diagnostics16172810"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16172810","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}